Congressional Testimony 2017
This section includes testimony by FDA officials before House and Senate Committees and Subcommittees. For testimony from previous years, see the FDA Archive.
September 2017
- 09/13/2017
Modernizing FDA's Regulation of Over-the-Counter Drugs
Janet Woodcock, M.D., before the House Energy and Commerce Committee, Subcommittee on Health
July 2017
- 07/27/2017
Antitrust Concerns and The FDA Approval Process
Scott Gottlieb, M.D., before the House Committee on the Judiciary, Subcommittee on Regulatory Reform, Commercial and Antitrust Law
June 2017
- 06/20/2017
President's Fiscal Year 2018 Budget Request (Senate)
Scott Gottlieb, M.D., before the Senate Committee on Appropriations, Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
May 2017
- 05/25/2017
The President's FY2018 Budget Request for FDA
Scott Gottlieb, M.D., before the House Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies - 05/23/2017
U.S. Public Health Response to the Zika Virus: Continuing Challenges
Luciana Borio, M.D., before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations - 05/02/2017
Examining Improvements to the Regulation of Medical Technologies
Jeffrey Shuren, M.D., J.D., before the House Committee on Energy and Commerce, Subcommittee on Health
March 2017
- 03/28/2017
Examining FDA’s Medical Device User Fee Program
Jeffrey Shuren, M.D., J.D. before the Committee on Energy and Commerce Subcommittee on Health, United States House of Representatives - 03/21/2017
Prescription Drug User Fee Act Reauthorization (PDUFA VI), Medical Device User Fee Act Reauthorization (MDUFA IV), Generic Drug User Fee Act Reauthorization (GDUFA II), and Biosimilar User Fee Act Reauthorization (BsUFA II)
Janet Woodcock, M.D., Peter Marks, M.D., Ph.D., and Jeffrey Shuren, M.D., J.D., before the Committee on Health, Education, Labor and Pensions, U.S. Senate - 03/02/2017
Generic Drug User Fee Act Reauthorization (GDUFA II), Biosimilar User Fee Act Reauthorization (BsUFA II)
Janet Woodcock, M.D. before the Committee on Energy and Commerce Subcommittee on Health, United States House of Representatives